Rodman & Renshaw initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $28 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target
- Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating
- Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating
- Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress
- Sagimet Biosciences reports Q4 EPS (29c), consensus (43c)